NCT00210327View on ClinicalTrials.gov

VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

November 30, 2008

Study Completion Date

April 30, 2009

Conditions
Lymphoma, Mucosa-Associated Lymphoid Tissue
Interventions
DRUG

Bortezomib (drug)

Trial Locations (1)

6500

Oncology Institute of Southern Switzerland (IOSI), Bellinzona

All Listed Sponsors
lead

International Extranodal Lymphoma Study Group (IELSG)

OTHER

NCT00210327 - VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy | Biotech Hunter | Biotech Hunter